Biotech Values

[DewDiligence]

There's a smidgen of hyperbole in the title of that WSJ piece, IMO.

Irrespective of US corporate-tax rates and other changes, medical-device companies should come out ahead under the Trump administration since the 2.3% ObamaCare excise tax on medical devices (which is not tax-deductible) is likely to be permanently killed.

The outcome for drug companies is less clear but it leans in the positive direction, IMO, particularly for smaller US companies such as ENTA who don't have the ability to finesse US corporate tax rates via complex inter-company dealings.